ArticleEndocrine2018

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.

Antongiulio Faggiano et al.PubMed ↗Publisher ↗

No numbers read from the abstract.